KZR-616-208
Not Recruiting
99 years or below
All
Phase
N/A
1 Location
Brief description of study
To evaluate the safety and tolerability of zetomipzomib in patients with autoimmune hepatitis (AIH) and to evaluate the efficacy of the drug in addition to standard-of-care in patients with AIH who have failed standard-of-care treatment. Target population = 3 subjects. Subjects will be randomized to either treatment or control and be on drug for 28 weeks. Study procedures include labs, physical examination, vitals, ECG, surveys, fibroscan, liver biopsies, and drug administration.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
04 Sep 2024.
Study ID: 852785
